| General Information | |
|---|---|
| ZINC ID | ZINC000028135488 |
| Molecular Weight (Da) | 462 |
| SMILES | CCCCCCNC(=O)c1cnc(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)c1 |
| Molecular Formula | C24Cl3N2O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 124.768 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 30 |
| LogP | 7.587 |
| Activity (Ki) in nM | 64.5654 |
| Polar Surface Area (PSA) | 41.99 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.108 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.25 |
| Ilogp | 4.59 |
| Xlogp3 | 7.64 |
| Wlogp | 7.69 |
| Mlogp | 5.24 |
| Silicos-it log p | 8.02 |
| Consensus log p | 6.63 |
| Esol log s | -7.37 |
| Esol solubility (mg/ml) | 0.0000199 |
| Esol solubility (mol/l) | 0.00000004 |
| Esol class | Poorly sol |
| Ali log s | -8.36 |
| Ali solubility (mg/ml) | 0.00000201 |
| Ali solubility (mol/l) | 4.35E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -11.18 |
| Silicos-it solubility (mg/ml) | 3.04E-09 |
| Silicos-it solubility (mol/l) | 6.59E-12 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.69 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.16 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.698 |
| Logd | 4.275 |
| Logp | 7.076 |
| F (20%) | 0.005 |
| F (30%) | 0.927 |
| Mdck | - |
| Ppb | 100.46% |
| Vdss | 2.292 |
| Fu | 1.15% |
| Cyp1a2-inh | 0.652 |
| Cyp1a2-sub | 0.213 |
| Cyp2c19-inh | 0.833 |
| Cyp2c19-sub | 0.059 |
| Cl | 4.178 |
| T12 | 0.026 |
| H-ht | 0.221 |
| Dili | 0.95 |
| Roa | 0.211 |
| Fdamdd | 0.384 |
| Skinsen | 0.112 |
| Ec | 0.003 |
| Ei | 0.036 |
| Respiratory | 0.032 |
| Bcf | 3.903 |
| Igc50 | 5.517 |
| Lc50 | 6.765 |
| Lc50dm | 6.196 |
| Nr-ar | 0.037 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.851 |
| Nr-aromatase | 0.842 |
| Nr-er | 0.694 |
| Nr-er-lbd | 0.024 |
| Nr-ppar-gamma | 0.797 |
| Sr-are | 0.9 |
| Sr-atad5 | 0.702 |
| Sr-hse | 0.684 |
| Sr-mmp | 0.917 |
| Sr-p53 | 0.916 |
| Vol | 448.043 |
| Dense | 1.027 |
| Flex | 0.474 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.349 |
| Synth | 2.129 |
| Fsp3 | 0.25 |
| Mce-18 | 18 |
| Natural product-likeness | -0.942 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |